All In Biotech

NDA 020998 · Upjohn

Celebrex

Celecoxib · Oral · Nonsteroidal Anti-inflammatory Drug

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Nov 21, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1998

Dec 31, 1998

Approved uses

7

Original approval plus efficacy supplements

Registered trials

631

125 Phase 3, 38 recruiting

FAERS reports

132,410

93,029 serious, 12,748 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS Cardiovascular Thrombotic Events • Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction, and stroke, which can be fatal. This risk may occur early in the treatment and may increase with duration of use [see Warnings and Precautions (5.1) ] . • CELEBREX is contraindicated in the setting of coronary artery bypass graft (CABG) surgery [see Contraindications (4) and Warnings and Precautions (5.1) ] . Gastrointestinal Bleeding, Ulceration, and Perforation • NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and...

What it is approved for

From the label in effect Nov 22, 2024.

CELEBREX is indicated CELEBREX is a nonsteroidal anti-inflammatory drug indicated for: • Osteoarthritis (OA) ( 1.1 ) • Rheumatoid Arthritis (RA) ( 1.2 ) • Juvenile Rheumatoid Arthritis (JRA) in patients 2 years and older ( 1.3 ) • Ankylosing Spondylitis (AS) ( 1.4 ) • Acute Pain (AP) ( 1.5 ) • Primary Dysmenorrhea (PD) ( 1.6 ) 1.1 Osteoarthritis (OA) For the management of the signs and symptoms of OA [see Clinical Studies (14.1) ] . 1.2 Rheumatoid Arthritis (RA) For the management of the signs and symptoms of RA [see Clinical Studies (14.2) ] . 1.3 Juvenile Rheumatoid Arthritis (JRA) For the management of the signs and symptoms of JRA in patients 2 years and older [see Clinical Studies (14.3) ] . 1.4 Ankylosing Spondylitis (AS) For the management of the signs and symptoms of AS [see Clinical Studies (14.4) ] . 1.5 Acute Pain For the management of acute pain in adults [see Clinical Studies (14.5) ] . 1.6 Primary Dysmenorrhea For the management of primary dysmenorrhea [see Clinical Studies (14.5) ] .

Mechanism: Celecoxib has analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of CELEBREX is believed to be due to inhibition of prostaglandin synthesis, primarily via inhibition of COX-2. Celecoxib is a potent inhibitor of prostaglandin synthesis in vitro . Celecoxib concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models. Prostaglandins are mediators of inflammation. Since celecoxib is an inhibitor of prostaglandin synthesis, its mode of action...

Therapeutic areas: Pain and anesthesia

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • CELEBREX · CELECOXIB 50MG · CAPSULE, ORAL · Prescription · TE AB
  • CELEBREX · CELECOXIB 200MG · CAPSULE, ORAL · Prescription · TE AB
  • CELEBREX · CELECOXIB 400MG · CAPSULE, ORAL · Prescription · TE AB
  • CELEBREX · CELECOXIB 100MG · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Celecoxib" as an intervention, any sponsor and status, largest first.

All 631 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective18,274
  • pain12,761
  • arthralgia11,408
  • fatigue10,286
  • nausea9,975
  • off label use8,305
  • drug hypersensitivity8,032
  • diarrhoea7,761
  • headache7,645
  • rheumatoid arthritis7,585
  • myocardial infarction7,052
  • rash6,675

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20043,673
20054,992
20064,651
20076,894
20082,482
20092,404
20106,011
20113,916
20125,869
20136,069
20146,647
20156,720
20166,777
20176,322
20186,844
20197,930
20208,497
20216,148
20226,500
20235,721
20246,578
20256,704
20264,058

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Celebrex (Celecoxib)

2024 spending

$13.8M

Beneficiaries

3,370

11,915 claims

Per beneficiary

$4,082

$14.39 per unit

View as table
YearSpending
2020$27,322,326
2021$19,072,505
2022$17,364,534
2023$16,190,429
2024$13,756,065

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,245 on PubMed

Sponsor: Upjohn

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.